PMID- 16393718
OWN - NLM
STAT- MEDLINE
DCOM- 20060307
LR  - 20151119
IS  - 0277-0903 (Print)
IS  - 0277-0903 (Linking)
VI  - 42
IP  - 10
DP  - 2005 Dec
TI  - Symptom control and improved functioning: the effect of omalizumab on 
      asthma-related quality of life (ARQL).
PG  - 823-7
AB  - This investigation evaluated variability in asthma-related quality-of-life (ARQL) 
      outcomes among patients randomized to omalizumab or placebo. Pooled data on the 
      Asthma Quality of Life Questionnaire (AQLQ) from two trials were used (n = 948). 
      Variability in ARQL outcomes was determined by categorizing AQLQ score changes 
      according to minimal clinically important difference (MCID: 0.5 points) and large 
      clinically important difference (LCID: 1.5 points) score changes. A greater 
      proportion of patients achieved improvement in every domain of AQLQ scores during 
      all periods with omalizumab compared with placebo. Omalizumab-treated patients 
      showed greater clinically important improvement in ARQL compared with patients 
      receiving placebo.
FAU - Luskin, Allan T
AU  - Luskin AT
AD  - University of Wisconsin, Madison, Wisconsin, USA. HealthyAirways@charter.net
FAU - Kosinski, Mark
AU  - Kosinski M
FAU - Bresnahan, Brian W
AU  - Bresnahan BW
FAU - Ashby, Mark
AU  - Ashby M
FAU - Wong, Dennis A
AU  - Wong DA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Asthma
JT  - The Journal of asthma : official journal of the Association for the Care of 
      Asthma
JID - 8106454
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2P471X1Z11 (Omalizumab)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Asthmatic Agents/*therapeutic use
MH  - Antibodies, Anti-Idiotypic
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Asthma/*drug therapy
MH  - Child
MH  - Female
MH  - Health Status
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Omalizumab
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
EDAT- 2006/01/06 09:00
MHDA- 2006/03/08 09:00
CRDT- 2006/01/06 09:00
PHST- 2006/01/06 09:00 [pubmed]
PHST- 2006/03/08 09:00 [medline]
PHST- 2006/01/06 09:00 [entrez]
AID - W5L181583G518450 [pii]
AID - 10.1080/02770900500369868 [doi]
PST - ppublish
SO  - J Asthma. 2005 Dec;42(10):823-7. doi: 10.1080/02770900500369868.